Lara E Davis
Overview
Explore the profile of Lara E Davis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
2218
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mowery Y, Ballman K, Hong A, Schuetze S, Wagner A, Monga V, et al.
Lancet
. 2024 Nov;
404(10467):2053-2064.
PMID: 39547252
Background: Approximately half of patients with localised, high-risk soft tissue sarcoma of the extremity develop metastases. We aimed to assess whether the addition of pembrolizumab to preoperative radiotherapy and surgery...
2.
Stefan K, Gordon R, Rolig A, Honkala A, Tailor D, Davis L, et al.
Front Immunol
. 2024 Nov;
15:1450118.
PMID: 39534596
Immunomodulating agents interact with the immune system and alter the outcome of specific immune processes. As our understanding of the immune system continues to evolve, there is a growing effort...
3.
Gelderblom H, Razak A, Taylor M, Bauer T, Wilky B, Martin-Broto J, et al.
Clin Cancer Res
. 2024 Jul;
30(18):3996-4004.
PMID: 38995311
Purpose: Tenosynovial giant cell tumor (TGCT) is a locally aggressive neoplasm caused by dysregulation of the colony-stimulating factor 1 (CSF1) gene and overexpression of the CSF1 ligand. Surgery is the...
4.
Meyers P, Federman N, Daw N, Anderson P, Davis L, Kim A, et al.
J Clin Oncol
. 2024 Jul;
42(31):3725-3734.
PMID: 38954782
Purpose: Ewing Sarcoma (ES), a rare cancer with a pathognomonic translocation resulting in the Ewing sarcoma gene (EWS)::FLI1 oncoprotein, has a poor prognosis in the relapsed/refractory (R/R) setting. Tokalas (TK)216...
5.
Kim C, Davis L, Albert C, Samuels B, Roberts J, Wagner M
Cancers (Basel)
. 2023 Oct;
15(20).
PMID: 37894411
Malignant bone tumors are commonly classified as pediatric or adolescent malignancies, and clinical trials for these diseases have generally focused on these populations. Of primary bone cancers, osteosarcoma is among...
6.
Smith B, Doung Y, Beckett B, Corless C, Davis L, Davis J
Cancer Invest
. 2023 Sep;
41(8):704-712.
PMID: 37668330
Spindle cell/sclerosing rhabdomyosarcoma (SSRMS) is a clinicopathologically and molecularly heterogeneous disease. Gene fusions have been identified in intraosseous SSRMS, consisting predominantly of /:: and ::. The former often follow an...
7.
Gounder M, Ratan R, Alcindor T, Schoffski P, van der Graaf W, Wilky B, et al.
N Engl J Med
. 2023 Mar;
388(10):898-912.
PMID: 36884323
Background: Desmoid tumors are rare, locally aggressive, highly recurrent soft-tissue tumors without approved treatments. Methods: We conducted a phase 3, international, double-blind, randomized, placebo-controlled trial of nirogacestat in adults with...
8.
Whiteway S, Weiss A, Ahmed S, Allen-Rhoades W, Avutu V, Cardona K, et al.
J Adolesc Young Adult Oncol
. 2023 Feb;
12(5):792-793.
PMID: 36724495
No abstract available.
9.
Li B, David L, Davis L, Xiao X
J Biol Chem
. 2022 Aug;
298(10):102434.
PMID: 36041632
Transcription dysregulation is common in sarcomas driven by oncogenic transcription factors. Clear cell sarcoma of soft tissue (CCSST) is a rare sarcoma with poor prognosis presently with no therapy. It...
10.
Attia S, Bolejack V, Ganjoo K, George S, Agulnik M, Rushing D, et al.
Cancer Med
. 2022 Aug;
12(2):1532-1539.
PMID: 35950293
Background: Regorafenib is one of several FDA-approved cancer therapies targeting multiple tyrosine kinases. However, there are few subtype-specific data regarding kinase inhibitor activity in sarcomas. We report results of a...